picankibart
Monoclonal antibody
Also known as IBI112
Evidence outlook
Approved: Moderate-to-severe plaque psoriasis (brand Pecondle) (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
track record: Reliable signal
Also in development:Ulcerative Colitis · Phase 2 · investigational in the US
Also approved (1)
- Moderate-to-severe plaque psoriasis (brand Pecondle)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05645627 NCT05645627 · Psoriasis CLEAR-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in 500 Chinese adults with moderate to severe plaque psoriasis. Patients received picankibart 200 mg or placebo for the first 16 weeks. The two primary endpoints at week 16 were at least 90% improvement in PASI and a clear or almost clear sPGA score. With picankibart, 80.3% reached PASI 90 and 93.5% reached sPGA 0/1, against 2.0% and 13.1% with placebo (p<0.0001 for both), so the trial met both primary endpoints. The response rates come from the peer-reviewed paper in the Journal of the American Academy of Dermatology and the p-values from the company announcement. Registry: NCT05645627 | 3 | Co-primary: proportion achieving PASI 90 and proportion achieving sPGA 0/1 (clear or minimal) at week 16 2023-08-09 | Co-primary 1, PASI 90 at week 16: 80.3% picankibart 200 mg vs 2.0% placebo (p<0.0001), met. Co-primary 2, sPGA 0/1 at week 16: 93.5% vs 13.1% (p<0.0001), met. Response rates from the JAAD paper; p-values from the Innovent release, as the paper abstract does not print them. | Reliable signal | link ↗ |
View 2 more trials
NCT06049810 NCT06049810 · Psoriasis After an initial response to picankibart, patients were randomized and blinded to either continue active treatment or switch to placebo; a hard, disease-defining skin-severity measure (PASI90) at Week 56 showed continued picankibart maintained response in about 90% of patients versus 38-52% after withdrawal to placebo (P<0.0001 for both comparisons). Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT06049810 | 3 | Percentage of participants with a Psoriasis Area and Severity Index (PASI) 90 Response (Week 56) 2025-04-29 | PASI 90 maintenance at Week 56: 89.3% (100 mg) and 90.1% (200 mg) picankibart-maintenance groups vs 37.7% and 51.7% in the corresponding randomized-withdrawal groups; P < 0.0001 for both comparisons | Reliable signal | link ↗ |
NCT07265284 NCT07265284 · Psoriasis Registry: NCT07265284 | 3 | Percentage of patients achieving Psoriasis Area and severity index(PASI) 75 at week 16; Percentage of patients achieving an static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) at Week 16 2026-09-30 | In progress: primary completion was expected 30 Sept 2026; results not posted | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other IL-23 p19 drugs
guselkumab, mirikizumab, risankizumab, tildrakizumab, HS-20137 and 7 more. Compare all 13 IL-23 p19 drugs
This mechanism is crowded: 12 other tracked programmes target it, 4 of them ahead of this one.
This drug's own stage for Psoriasis: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Picankibart: this drug | Phase 3 | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT06049810: PASI 90 maintenance at Week 56: 89.3% (100 mg) and 90.1% (200 mg) picankibart-maintenance groups vs 37.7% and 51.7% in the corresponding randomized-withdrawal groups; P < 0.0001 for both comparisons NCT05645627: Co-primary 1, PASI 90 at week 16: 80.3% picankibart 200 mg vs 2.0% placebo (p<0.0001), met. Co-primary 2, sPGA 0/1 at week 16: 93.5% vs 13.1% (p<0.0001), met. Response rates from the JAAD paper; p-values from the Innovent release, as the paper abstract does not print them. | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | Partial signal | NCT00195676: PGA 0/1 at 16 weeks after adalimumab retreatment: 89% in patients without relapse vs 69% in patients who relapsed; median time to relapse 141 days (178/285 stable-control patients relapsed) NCT00237887: REVEAL: PASI 75 response rates of 71% after 16 weeks and 70% after 24 weeks of treatment with adalimumab 40 mg every other week. | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | Weak signal | No reviewed efficacy summary in this indication | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | Reliable signal | NCT03701763: Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 (Baseline to Week 16): Apremilast 33.1% vs Placebo 11.5% NCT03777436: Percentage of Participants With a Modified sPGA-G Response at Week 16 (Baseline and Week 16 of the Placebo-controlled Phase): Placebo-controlled Phase: Apremilast 30 mg 39.6% (95% CI 31.2 to 48) vs Placebo-controlled Phase: Placebo 19.5% (95% CI 12.7 to 26.3) | |
| Betamethasone Dipropionate Emollient Spray (Sernivo) | Approved | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | Reliable signal | NCT03412747: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W + Bimekizumab 320 mg Q4W/Q8W (RS) 86.2% vs Adalimumab (RS) 47.2% NCT03370133: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W (RS) 85% vs Placebo (RS) 4.8% vs Ustekinumab (RS) 49.7% | |
| Brodalumab (Siliq) | Approved | Monoclonal antibody | IL-17 receptor A | Partial signal | NCT02982005: Coprimary endpoints at week 12: PASI 75 and sPGA success achieved by 92.5% (brodalumab 210mg Q2W) vs 0% (placebo), significantly higher | |
| Calcipotriene / Betamethasone Dipropionate Cream (Wynzora) | Approved | Small molecule | Vitamin D receptor + Glucocorticoid receptor | Partial signal | NCT03802344: Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score (8 Weeks): MC2-01 Cream -67.5% (Standard Error 20.8) vs Cal/BDP Combination -63.5% (Standard Error 22.2) vs Vehicle -11.7% (Standard Error 21.9) NCT03308799: PGA treatment success at week 8: 37.4% with CAL/BDP cream (MC2-01) vs 22.8% with CAL/BDP topical suspension (P<0.0001) and 3.7% with vehicle (P<0.0001) (Stein Gold et al., J Drugs Dermatol 2021). | |
| Calcipotriene / Betamethasone Dipropionate Foam (Enstilar) | Approved | Small molecule | Vitamin D receptor + Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Calcipotriol / Betamethasone Dipropionate Gel (Taclonex) | Approved | Small molecule | Vitamin D receptor + Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | Reliable signal | NCT02326298: PASI 75 at Week 16 (CIMPASI-1): certolizumab pegol 200mg Q2W 66.5%, 400mg Q2W 75.8%, placebo 6.5% (P<0.0001 for both doses vs placebo). NCT02326272: PASI 75 at Week 16 (CIMPASI-2): certolizumab pegol 200mg Q2W 81.4%, 400mg Q2W 82.6%, placebo 11.6% (P<0.0001 for both doses vs placebo). | |
| Desoximetasone (Topicort Spray) | Approved | Small molecule | Glucocorticoid receptor agonist | Partial signal | NCT02618759: Number of Patients in Each Treatment That Have Clinical Success Based on IGA at Day 28 ± 2 (28 Days): DSXS1505 10/60 (16.7%) vs Placebo 3/59 (5.1%) missed phase 3 result · pivotal pending NCT02932462: Clinical Success in Patients With Moderate and Severe Scalp Psoriasis (from baseline to study day 29): DSXS 1535 41/106 (38.7%) vs Placebo 43/126 (34.1%) missed phase 3 result · pivotal pending | |
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | Reliable signal | NCT04167462: The Percentage of Participants With sPGA Response of 0 or 1 (At week 16): Arm 1: BMS-986165 55.6% (95% CI 47.4 to 63.7) vs Arm 2: Placebo 6.8% (95% CI 1 to 12.5) NCT03611751: The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1) (Week 16): BMS-986165 253/511 (49.5%) vs Placebo 22/255 (8.6%) | |
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | Weak signal | NCT00111436: Primary endpoint (incidence of adverse events/lab changes) in this 912-patient open-label long-term safety extension (Leonardi et al. 2010, cited by this PMC review), exactly matching this NCT's registered enrollment (912) and design (open-label extension, safety of 50mg QW/BIW etanercept, 48-72 weeks): well tolerated, no significant AE/infection-rate difference between dose groups, no TB/opportunistic infection/demyelination/lymphoma cases. | |
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT02203032: Primary endpoint (NAVIGATE trial), mean number of visits Week 28-40 with IGA 0/1 and >=2-grade improvement: guselkumab 1.5 (SD 1.57, n=135) vs continued ustekinumab 0.7 (SD 1.26, n=133); row mean score test P<0.001. NCT02207244: Week 16 co-primary endpoints (VOYAGE 2, NCT02207244): IGA 0/1 84.1% guselkumab vs 8.5% placebo (p<0.001); PASI 90 70.0% guselkumab vs 2.4% placebo (p<0.001) | |
| Halobetasol Propionate Foam (Lexette) | ApprovedUS marketing discontinued | Small molecule | Glucocorticoid receptor | Reliable signal | NCT02742441: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 30.7% vs Vehicle Foam 7.4% NCT02368210: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 25.3% vs Vehicle Foam 3.9% | |
| Halobetasol Propionate Lotion (Bryhali) | Approved | Small molecule | Glucocorticoid receptor | Partial signal | NCT02514577: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 36.5% vs IDP-122 Vehicle Lotion 8.13% NCT02515097: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 38.41% vs IDP-122 Vehicle Lotion 11.99% | |
| Halobetasol Propionate / Tazarotene (Duobrii) | Approved | Small molecule | Glucocorticoid receptor + retinoic acid receptor | Partial signal | NCT02462122: Treatment success at week 8 (at least a 2-grade IGA improvement to clear or almost clear), halobetasol propionate 0.01%/tazarotene 0.045% lotion vs vehicle (study 2): 45.3% vs 12.5%, P<.001 (Gold et al., JAAD 2018; CT.gov posted 35.76%/6.98% and 45.33%/12.51%). NCT02462070: Treatment success at week 8 (at least a 2-grade IGA improvement to clear or almost clear), halobetasol propionate 0.01%/tazarotene 0.045% lotion vs vehicle (study 1): 35.8% vs 7.0%, P<.001 (Gold et al., JAAD 2018; CT.gov posted 35.76%/6.98% and 45.33%/12.51%). | |
| Icotrokinra (Icotyde) | Approved | Peptide | IL-23 receptor | Reliable signal | NCT06095115: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16): JNJ-77242113 200 mg 64.7% NCT06095102: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16): JNJ-77242113 200 mg 56.7% vs Placebo 5.8% | |
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT01177800: PASI 75 response at week 10: 81.0% infliximab (5 mg/kg) vs 2.2% placebo (P < 0.001) NCT00106847: Primary endpoint (PASI 75 at week 10), EXPRESS II trial -- official title fetched directly from the CT.gov API for this NCT matches word-for-word ('...Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance Infliximab Therapy in Patients With Plaque-Type Psoriasis'): infliximab 3mg/kg 70%, 5mg/kg 75%, vs placebo 2% (P<0.001). | |
| Infliximab-Abda (Renflexis) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Axxq (Avsola) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Dyyb (Inflectra) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Qbtx (Ixifi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Ixekizumab (Taltz) | Approved | Monoclonal antibody | IL-17 | Reliable signal | NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo. NCT01474512: Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA) (Week 12): Ixe Q4W 76.4% | Ixe Q2W 81.8% vs Placebo 3.2% | |
| Risankizumab (Skyrizi) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT02672852: Co-primary endpoints at Week 16 (IMMhance study): PASI 90 73% risankizumab vs 2% placebo; sPGA 0/1 84% risankizumab vs 7% placebo; both p<0.001 NCT02684370: PASI90 at Week 16 (UltIMMa-1 trial, NCT02684370): risankizumab 75.3% vs placebo 4.9% vs ustekinumab 42.0% (p<0.0001 vs both comparators) | |
| Roflumilast (Zoryve Foam) | Approved | Small molecule | PDE4 | not yet graded | No reviewed efficacy summary in this indication | |
| Roflumilast (Zoryve) | Approved | Small molecule | PDE4 | Partial signal | NCT04211389: Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Roflumilast Cream 0.3% 99/264 (37.5%) vs Vehicle Cream 9/131 (6.9%) NCT04211363: Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8 (Baseline (Day 1) and Week 8): Rofumilast Cream 0.3% 108/255 (42.4%) vs Vehicle Cream 8/132 (6.1%) | |
| Secukinumab (Cosentyx) | Approved | Monoclonal antibody | IL-17 | Reliable signal | NCT01358578: Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks): AIN457 150mg 219/327 (67.0%) | AIN457 300mg 249/323 (77.1%) vs Placebo 16/324 (4.9%) NCT01365455: Percentage of Participants Who Achieved >75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks (12 weeks): AIN457 150 mg 71.6% | AIN457 300 mg 81.6% vs Placebo 4.5% | |
| Spesolimab (Spevigo) | Approved | Monoclonal antibody | IL-36 receptor | Reliable signal | NCT03782792: Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1 (At Week 1.): Spesolimab 900 mg i.v SD 54.3% (95% CI 38.2% to 69.5%) vs Placebo 5.6% (95% CI 1% to 25.8%) | |
| Tapinarof | Approved | Small molecule | Aryl hydrocarbon receptor, Aryl Hydrocarbon Receptor Agonist | Reliable signal | NCT03956355: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation (Baseline to Week 12): Tapinarof (DMVT-505) 35.4% (Standard Error 2.75) vs Vehicle Cream 6% (Standard Error 2.08) NCT03983980: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation (Baseline to Week 12): Tapinarof (DMVT-505) Cream Group 40.2% (Standard Error 2.82) vs Vehicle Cream Group 6.3% (Standard Error 1.99) | |
| Tildrakizumab (Ilumya) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT01722331: Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)): Tildrakizumab 200 mg (Part 1) 62.3% | Tildrakizumab 100 mg (Part 1) 63.8% vs Placebo (Part 1) 5.8% NCT01729754: Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12 (Part 1) (Week 12): Tildrakizumab 200 mg 65.6% | Tildrakizumab 100 mg 61.2% vs Placebo 5.8% | Etanercept 50 mg 48.2% | |
| Ustekinumab (Stelara) | Approved | Monoclonal antibody | IL-12 p40 | Reliable signal | NCT00307437: PASI 75 at Week 12 (intent-to-treat, PHOENIX 2 trial): placebo 15/410 vs ustekinumab 45 mg 273/409 vs ustekinumab 90 mg 311/411; p<0.001 for each dose vs placebo. NCT00267969: PASI 75 at week 12: ustekinumab 45mg 67.1% vs placebo 3.1% (difference 63.9%, 95% CI 57.8-70.1, p<0.0001); ustekinumab 90mg 66.4% vs placebo 3.1% (difference 63.3%, 95% CI 57.1-69.4, p<0.0001). | |
| Ustekinumab-Aauz (Otulfi) | Approved | — | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aekn (Selarsdi) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Auub (Wezlana) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Hmny (Starjemza) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Srlf (Imuldosa) | Approved | Monoclonal antibody | IL-12 p40 | Reliable signal | Featured results are non-efficacy only in this race | |
| Ustekinumab-Stba (Steqeyma) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Ttwe (Pyzchiva) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Amdokitug (Yisaituo) | Phase 3 | Monoclonal antibody | IL-17A | not yet graded | No reviewed efficacy summary in this indication | |
| Dimethyl Fumarate (Skilarence) | Phase 3 | Small molecule | Nrf2 pathway (fumaric acid ester) | not yet graded | No reviewed efficacy summary in this indication | |
| Ebdarokimab | Phase 3 | Monoclonal antibody | IL-12/23 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Envudeucitinib | Phase 3 | Small molecule | TYK2 | Reliable signal | NCT06586112: PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all) NCT06588738: ONWARD2, week 16 co-primary endpoints vs placebo (intention-to-treat, nonresponder imputation): PASI 75 70.4% with envudeucitinib 40 mg twice daily (n=433) vs 13.7% with placebo (n=211); sPGA 0/1 57.3% vs 5.7%; both P < 0.0001 (Cochran-Mantel-Haenszel). PASI 90: 53.1% vs 4.3%. Apremilast 30 mg twice daily (n=215): PASI 75 38.6%, sPGA 0/1 27.4% (Alumis AAD 2026 late-breaking presentation). | |
| Fadeucravacitinib | Phase 3 | Small molecule | TYK2 | Partial signal | NCT06109818: PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved | |
| Gumokimab | Phase 3 | Monoclonal antibody | IL-17A | Partial signal | NCT06066125: PASI 75 response at Week 12: 94.6% with gumokimab; PASI 100: 47.7% | |
| HB0017 | Phase 3 | Monoclonal antibody | IL-17A | Partial signal | NCT05531682: Co-primaries PASI 90 and sPGA 0/1 at week 12: HB0017 300 mg (n=41) vs placebo (n=40), PASI 90 69.4% vs 1.0% and sPGA 0/1 78.2% vs 1.1%, both P<0.001. The registry lists three HB0017 dosing regimens and 160 participants; the abstract reports one regimen in 81 patients and gives no result for the other two regimens. | |
| HS-10374 | Phase 3 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| HS-20137 | Phase 3 | Monoclonal antibody | IL-23 p19 | not yet graded | No reviewed efficacy summary in this indication | |
| Imsidolimab | Phase 3 | Monoclonal antibody | IL-36 receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Lecankitug | Phase 3 | Monoclonal antibody | IL-17A/F | not yet graded | No reviewed efficacy summary in this indication | |
| Mufemilast | Phase 3 | Small molecule | PDE4 | Partial signal | NCT04839328: PASI75 比例分别为 53.6% vs 16.0%,sPGA 0/1 率分别为 31.3% vs 6.4% (PASI75 at week 16: Hemay005 53.6% vs placebo 16.0%; sPGA 0/1: 31.3% vs 6.4%) | |
| Netakimab | Phase 3 | Monoclonal antibody | IL-17 | Reliable signal | NCT03390101: • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment (week 12): BCD-085 Q2W 66/85 (77.6%) | BCD-085 Q4W 70/84 (83.3%) vs Placebo 0/44 (0.0%) | |
| Nomelcitinib (D-2570) | Phase 3 | Small molecule | TYK2 | Partial signal | NCT06278350: Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001) | |
| Piclidenoson | Phase 3 | Small molecule | Adenosine A3 receptor | Partial signal | NCT03168256: PASI 75 at week 16: 9.7% (3mg) vs 2.6% (placebo), p=0.037; linear improvement through week 32 (PASI 75: 19.6%) NCT01265667: PASI 75 at week 12: CF101 2 mg 8.5% vs placebo 6.9%, P=0.621, tested at a 0.035 significance level (J Drugs Dermatol 2016). missed | |
| Ponesimod | Phase 3 | Small molecule | S1P receptor | not yet graded | No reviewed efficacy summary in this indication | |
| QL2106 | Phase 3 | Monoclonal antibody | IL-23 p19 | not yet graded | No reviewed efficacy summary in this indication | |
| Avrukibart | Phase 2 | Monoclonal antibody | IL-23 p19 | Partial signal | NCT07090330: Primary endpoint PASI 100 at week 16 (interim analysis): 63.5% (40/63) with ORKA-001 vs 1 of 21 with placebo (2026-04-27). | |
| SHR-1139 | Phase 2 | Monoclonal antibody | IL-23 p19, IL-36 receptor | Weak signal | No reviewed efficacy summary in this indication |
Large race: only the 67 furthest-along competitors are listed; 52 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
6 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow picankibart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent